Home » FDA Grants Two Orphan Drug Designations for Bayer’s Riociguat
FDA Grants Two Orphan Drug Designations for Bayer’s Riociguat
A subsidiary of Bayer has received two orphan drug designations from the FDA for riociguat, which purports to treat pulmonary hypertension and thromboembolic pulmonary hypertension.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May